| scholarly article | Q13442814 |
| P50 | author | Dimitrios A Tsakiris | Q88498823 |
| Sara C Meyer | Q56386950 | ||
| Jakob R. Passweg | Q67905482 | ||
| P2093 | author name string | Thomas Lehmann | |
| Radek C Skoda | |||
| Patricia Muesser | |||
| Eva Steinmann | |||
| P2860 | cites work | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 | ||
| Pathogenesis of myeloproliferative neoplasms | Q26799656 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Efficacy and safety of low-dose aspirin in polycythemia vera | Q28166691 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Jak2 is essential for signaling through a variety of cytokine receptors | Q28270987 | ||
| A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia | Q28285557 | ||
| Heparin-associated thrombocytopenia in a patient with polycythemia vera: the importance of a marked drop in platelet count | Q28328081 | ||
| Cerebral venous thrombosis due to heparin-induced thrombocytopenia | Q28331552 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Atomic description of the immune complex involved in heparin-induced thrombocytopenia | Q30665349 | ||
| Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. | Q33332910 | ||
| ET gets HIT--thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). | Q33335186 | ||
| Heparin‐induced thrombocytopenia: pathogenesis and management | Q33348049 | ||
| Heparin-induced thrombocytopenia and thrombosis in a patient with polycythemia vera | Q33362328 | ||
| Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis | Q33367004 | ||
| The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study | Q33367395 | ||
| Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia | Q33372034 | ||
| Beyond the platelet count: heparin antibodies as independent risk predictors | Q33375433 | ||
| Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? | Q33378189 | ||
| The temporal profile of the anti-PF4/heparin immune response | Q33382566 | ||
| Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia | Q33387089 | ||
| The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia | Q33387334 | ||
| Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis | Q33388134 | ||
| Budd-Chiari syndrome and heparin-induced thrombocytopenia in polycythemia vera: successful treatment with repeated TIPS and interferon alpha | Q33388289 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia | Q33392361 | ||
| Cerebral venous thrombosis due to essential thrombocythemia and worsened by heparin-induced thrombocytopenia and thrombosis | Q33393189 | ||
| Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study | Q33394025 | ||
| Plasma .BETA.-thromboglobulin and platelet factor 4 in patients with chronic renal failure and effect of hemodialysis | Q72660861 | ||
| Heparin-induced thrombocytopenia without thrombocytopenia in a patient with essential thrombocythemia | Q73180005 | ||
| Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia | Q73385675 | ||
| Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders | Q74129093 | ||
| Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients | Q74456061 | ||
| Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters | Q79339926 | ||
| Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery | Q81530809 | ||
| Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors | Q82523723 | ||
| Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. | Q46180323 | ||
| Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia | Q46847956 | ||
| Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. | Q46930457 | ||
| Knee replacement and HIT without heparin | Q48229126 | ||
| Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. | Q50938987 | ||
| Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. | Q50944772 | ||
| Are Myeloproliferative neoplasms a risk factor for Heparin-Induced Thrombocytopenia? | Q52992501 | ||
| Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and O | Q56960816 | ||
| Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera | Q63367974 | ||
| Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia | Q68717742 | ||
| Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease | Q33395715 | ||
| Heparin-induced thrombocytopenia in essential thrombocytosis | Q33400288 | ||
| Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia | Q33405047 | ||
| Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia | Q33406904 | ||
| Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder | Q33414277 | ||
| Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia | Q33427182 | ||
| Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery | Q33428351 | ||
| Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program | Q33429569 | ||
| Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors | Q33433524 | ||
| Heparin-induced thrombocytopenia: research and clinical updates. | Q33437334 | ||
| Platelet Factor 4/Heparin Antibodies in Blood Bank Donors | Q33453074 | ||
| Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin | Q33489438 | ||
| Cranial sinus thrombosis associated with essential thrombocythemia followed by heparin-associated thrombocytopenia | Q33496310 | ||
| Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis | Q33697252 | ||
| Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 | ||
| Thrombohemorrhagic complications of myeloproliferative disorders | Q34136065 | ||
| Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo | Q34237772 | ||
| MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
| JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response | Q35163764 | ||
| Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. | Q36831712 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia | Q37349414 | ||
| From leeches to personalized medicine: evolving concepts in the management of polycythemia vera | Q37555790 | ||
| Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease. | Q37615123 | ||
| Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. | Q37708936 | ||
| Thrombotic disease in the myeloproliferative neoplasms. | Q38066925 | ||
| Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management | Q38100371 | ||
| Thrombosis in myeloproliferative neoplasms | Q38194509 | ||
| Myeloproliferative Neoplasms: A Contemporary Review | Q38548597 | ||
| Molecular biomarkers of thrombosis in myeloproliferative neoplasms | Q38805429 | ||
| Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. | Q38811734 | ||
| Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis | Q38816577 | ||
| Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). | Q39542698 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. | Q43898090 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 9876819 | |
| P577 | publication date | 2017-06-18 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera | |
| P478 | volume | 2017 |
Search more.